A1309 were purposefully chosen as they are non-malignant, non-transformed cell line that have been engineered to contain additional predisposing genetic alterations (see Methods) typically occurring early in CRC development that may synergise with EMI1 loss. Here, FBXO5 is linked to colorectal carcinoma.